Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Data breaches targeting pharma companies are ‘rampant,’ report says

By Brian Buntz | January 27, 2022

Laboratory image

Photo by Edward Jenner from Pexels

For pharmaceutical companies, cyberattacks can get expensive quickly. 

In 2021, the average cost of a data breach was $5 million, which is the third-highest of any industry, according to the IBM Cost of a Data Breach report. 

Cyberattacks can also cause operational disruptions. For example, in 2017, Merck & Co. (NYSE: MRK) struggled to keep up with demand for hepatitis B vaccine because it was a victim of Notpetya ransomware. Merck estimated the damages from that attack to be roughly $1.4 billion. 

Breaches in the pharma industry are rampant, concludes a recently published report from the cybersecurity firm Constella Intelligence (Los Altos, California), which analyzes data exposures, breaches and leakages within the industry from January 2018 to September 2021. In that time frame, the company identified 9,030 breaches or leakages and more than 4,500,000 exposed records containing everything from passwords to financial data. 

Some pharmaceutical industry employees have played a role in the breaches by using corporate email accounts to register for sports, travel, gaming, entertainment sites.   

Jonathan Nelson

Jonathan Nelson

The widespread use of corporate email accounts for non-business services is “frustratingly common,” said Jonathan Nelson, a digital intelligence specialist at Constella. 

The practice increases the risk of data breaches, which cybercriminals can use for everything from phishing attacks to account takeovers. 

Based on a survey of 78 pharma execs working at Fortune 500 companies, 58% had their data exposed, according to Constella. Of those with exposed data, almost one out of three had their passwords compromised.

“Executives are a critical vector for cybercriminals,” Nelson said. 

Cybercriminals aim to target executives because they tend to have broad access to IT systems and can be exploited in impersonation attacks. 

Also complicating matters is the rise in virtual work during the pandemic and poorly-secured Internet of Things-based Pharma 4.0 initiatives, leading to an increase in attack surface. 

In addition, the pandemic has also raised the profile of intellectual property in cybercriminals’ minds. The data linked to the development of a COVID-19 vaccine, for instance, is “incredibly valuable,” Nelson said.  

Constella Intelligence data breaches

Image courtesy of Constella Intelligence


Filed Under: Drug Discovery and Development
Tagged With: breaches, Constella, covid-19, cybercriminals, Cybersecurity, data breaches, e-mail, exposed records
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Unlocking PROTAC potential through better delivery
2026 PharmSci 360 adds tracks on research credibility and post-animal drug development
A pharmaceutical technician performs aseptic compounding inside a sterile biosafety cabinet, preparing a cell culture for biologic drug development under strict quality control conditions.
FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide
The division of the staff into two divisions of the company. Mass layoffs, work optimization and cost reduction. Crisis and downsizing of business. Reduce and save business. Keep the best employees.
As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE